APO Research
Talk to an analyst

APO RESEARCH · REPORT

Taditional Chinese Medicine (TCM) for COVID-19

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Taditional Chinese Medicine (TCM) for COVID-19 Market Outlook and Growth Opportunities 2026

31 December 2025196 pages

Choose your research edition.

Industry ResearchTaditional Chinese Medicine (TCM) for COVID-19 Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Taditional Chinese Medicine (TCM) for COVID-19 Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Taditional Chinese Medicine (TCM) for COVID-19 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Taditional Chinese Medicine (TCM) for COVID-19 Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Taditional Chinese Medicine (TCM) for COVID-19 Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Taditional Chinese Medicine (TCM) for COVID-19 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Taditional Chinese Medicine (TCM) for COVID-19 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Taditional Chinese Medicine (TCM) for COVID-19 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Taditional Chinese Medicine (TCM) for COVID-19 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Taditional Chinese Medicine (TCM) for COVID-19 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Taditional Chinese Medicine (TCM) for COVID-19 market include China Beijing Tong Ren Tang Group Co., Ltd., Yiling Pharmaceutical, Southwest Pharmaceutical, Beijing Juxiechang Pharmaceutical, Jiuzhitang, Jiangsu Jichuan Holding Group Co., Ltd., Tianjin Chase Sun Pharmaceutical, Guizhou Yibai Pharmaceutical and Sunflower, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Taditional Chinese Medicine (TCM) for COVID-19 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Taditional Chinese Medicine (TCM) for COVID-19 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Taditional Chinese Medicine (TCM) for COVID-19 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Taditional Chinese Medicine (TCM) for COVID-19 market.

Taditional Chinese Medicine (TCM) for COVID-19 Segment by Company

China Beijing Tong Ren Tang Group Co., Ltd.

Yiling Pharmaceutical

Southwest Pharmaceutical

Beijing Juxiechang Pharmaceutical

Jiuzhitang

Jiangsu Jichuan Holding Group Co., Ltd.

Tianjin Chase Sun Pharmaceutical

Guizhou Yibai Pharmaceutical

Sunflower

Qingfeng Pharmaceutical Group

Jiren Pharmaceutical Group

Taditional Chinese Medicine (TCM) for COVID-19 Segment by Type

Jinhua Qinggan Granules

Lianhua Qingwen Capsule

Xuebijing Injection

TCM Prescription

Other

Taditional Chinese Medicine (TCM) for COVID-19 Segment by Application

Hospital

Clinic

Other

Taditional Chinese Medicine (TCM) for COVID-19 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Taditional Chinese Medicine (TCM) for COVID-19 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Taditional Chinese Medicine (TCM) for COVID-19 key companies, revenue, market share, and recent developments.

3. To split the Taditional Chinese Medicine (TCM) for COVID-19 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Taditional Chinese Medicine (TCM) for COVID-19 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Taditional Chinese Medicine (TCM) for COVID-19 significant trends, drivers, influence factors in global and regions.

6. To analyze Taditional Chinese Medicine (TCM) for COVID-19 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Taditional Chinese Medicine (TCM) for COVID-19 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Taditional Chinese Medicine (TCM) for COVID-19 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Taditional Chinese Medicine (TCM) for COVID-19.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Taditional Chinese Medicine (TCM) for COVID-19 industry.

Chapter 3: Detailed analysis of Taditional Chinese Medicine (TCM) for COVID-19 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Taditional Chinese Medicine (TCM) for COVID-19 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Taditional Chinese Medicine (TCM) for COVID-19 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Taditional Chinese Medicine (TCM) for COVID-19 Industry Trends Table 2. Taditional Chinese Medicine (TCM) for COVID-19 Industry Drivers Table 3. Taditional Chinese Medicine (TCM) for COVID-19 Industry Opportunities and Challenges Table 4. Taditional Chinese Medicine (TCM) for COVID-19 Industry Restraints Table 5. Global Taditional Chinese Medicine (TCM) for COVID-19 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Taditional Chinese Medicine (TCM) for COVID-19 Revenue Share by Company (2021-2026) Table 7. Global Taditional Chinese Medicine (TCM) for COVID-19 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Taditional Chinese Medicine (TCM) for COVID-19 Key Company Manufacturing Base & Headquarters Table 9. Global Taditional Chinese Medicine (TCM) for COVID-19 Company, Product Type & Application Table 10. Global Taditional Chinese Medicine (TCM) for COVID-19 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Taditional Chinese Medicine (TCM) for COVID-19 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Jinhua Qinggan Granules Table 15. Significant Companies of Lianhua Qingwen Capsule Table 16. Significant Companies of Xuebijing Injection Table 17. Significant Companies of TCM Prescription Table 18. Significant Companies of Other Table 19. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type (2021-2026) Table 23. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Clinic Table 26. Significant Companies of Other Table 27. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application (2021-2026) Table 31. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application (2027-2032) Table 32. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Region (2021-2026) Table 35. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Region (2027-2032) Table 37. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Market Share by Country (2021-2026) Table 40. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Market Share by Country (2027-2032) Table 42. China Beijing Tong Ren Tang Group Co., Ltd. Company Information Table 43. China Beijing Tong Ren Tang Group Co., Ltd. Business Overview Table 44. China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 46. China Beijing Tong Ren Tang Group Co., Ltd. Recent Development Table 47. Yiling Pharmaceutical Company Information Table 48. Yiling Pharmaceutical Business Overview Table 49. Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 51. Yiling Pharmaceutical Recent Development Table 52. Southwest Pharmaceutical Company Information Table 53. Southwest Pharmaceutical Business Overview Table 54. Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 56. Southwest Pharmaceutical Recent Development Table 57. Beijing Juxiechang Pharmaceutical Company Information Table 58. Beijing Juxiechang Pharmaceutical Business Overview Table 59. Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 61. Beijing Juxiechang Pharmaceutical Recent Development Table 62. Jiuzhitang Company Information Table 63. Jiuzhitang Business Overview Table 64. Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 66. Jiuzhitang Recent Development Table 67. Jiangsu Jichuan Holding Group Co., Ltd. Company Information Table 68. Jiangsu Jichuan Holding Group Co., Ltd. Business Overview Table 69. Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 71. Jiangsu Jichuan Holding Group Co., Ltd. Recent Development Table 72. Tianjin Chase Sun Pharmaceutical Company Information Table 73. Tianjin Chase Sun Pharmaceutical Business Overview Table 74. Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 76. Tianjin Chase Sun Pharmaceutical Recent Development Table 77. Guizhou Yibai Pharmaceutical Company Information Table 78. Guizhou Yibai Pharmaceutical Business Overview Table 79. Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 81. Guizhou Yibai Pharmaceutical Recent Development Table 82. Sunflower Company Information Table 83. Sunflower Business Overview Table 84. Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 86. Sunflower Recent Development Table 87. Qingfeng Pharmaceutical Group Company Information Table 88. Qingfeng Pharmaceutical Group Business Overview Table 89. Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 91. Qingfeng Pharmaceutical Group Recent Development Table 92. Jiren Pharmaceutical Group Company Information Table 93. Jiren Pharmaceutical Group Business Overview Table 94. Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio Table 96. Jiren Pharmaceutical Group Recent Development Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Taditional Chinese Medicine (TCM) for COVID-19 Product Image Figure 2. Global Taditional Chinese Medicine (TCM) for COVID-19 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Taditional Chinese Medicine (TCM) for COVID-19 Market Size (2021-2032) & (US$ Million) Figure 4. Global Taditional Chinese Medicine (TCM) for COVID-19 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Jinhua Qinggan Granules Image Figure 8. Lianhua Qingwen Capsule Image Figure 9. Xuebijing Injection Image Figure 10. TCM Prescription Image Figure 11. Other Image Figure 12. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Clinic Image Figure 17. Other Image Figure 18. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application (2021-2032) Figure 21. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032) & (US$ Million) Figure 24. North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032) & (US$ Million) Figure 30. South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Jinhua Qinggan Granules
  • Lianhua Qingwen Capsule
  • Xuebijing Injection
  • TCM Prescription
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • China Beijing Tong Ren Tang Group Co., Ltd.
  • Yiling Pharmaceutical
  • Southwest Pharmaceutical
  • Beijing Juxiechang Pharmaceutical
  • Jiuzhitang
  • Jiangsu Jichuan Holding Group Co., Ltd.
  • Tianjin Chase Sun Pharmaceutical
  • Guizhou Yibai Pharmaceutical
  • Sunflower
  • Qingfeng Pharmaceutical Group
  • Jiren Pharmaceutical Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Taditional Chinese Medicine (TCM) for COVID-19 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Taditional Chinese Medicine (TCM) for COVID-19 Market Dynamics
  1. 2.1 Taditional Chinese Medicine (TCM) for COVID-19 Industry Trends
  2. 2.2 Taditional Chinese Medicine (TCM) for COVID-19 Industry Drivers
  3. 2.3 Taditional Chinese Medicine (TCM) for COVID-19 Industry Opportunities and Challenges
  4. 2.4 Taditional Chinese Medicine (TCM) for COVID-19 Industry Restraints
3 Taditional Chinese Medicine (TCM) for COVID-19 Market by Company
  1. 3.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Company Revenue Ranking in 2025
  2. 3.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Revenue by Company (2021-2026)
  3. 3.3 Global Taditional Chinese Medicine (TCM) for COVID-19 Company Ranking (2024-2026)
  4. 3.4 Global Taditional Chinese Medicine (TCM) for COVID-19 Company Manufacturing Base and Headquarters
  5. 3.5 Global Taditional Chinese Medicine (TCM) for COVID-19 Company Product Type and Application
  6. 3.6 Global Taditional Chinese Medicine (TCM) for COVID-19 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Taditional Chinese Medicine (TCM) for COVID-19 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Taditional Chinese Medicine (TCM) for COVID-19 Market by Type
  1. 4.1 Taditional Chinese Medicine (TCM) for COVID-19 Type Introduction
  2. 4.1.1 Jinhua Qinggan Granules
  3. 4.1.2 Lianhua Qingwen Capsule
  4. 4.1.3 Xuebijing Injection
  5. 4.1.4 TCM Prescription
  6. 4.1.5 Other
  7. 4.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type
  8. 4.2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2021-2032)
  10. 4.2.3 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type (2021-2032)
5 Taditional Chinese Medicine (TCM) for COVID-19 Market by Application
  1. 5.1 Taditional Chinese Medicine (TCM) for COVID-19 Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application
  6. 5.2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2021-2032)
  8. 5.2.3 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application (2021-2032)
6 Taditional Chinese Medicine (TCM) for COVID-19 Regional Value Analysis
  1. 6.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032)
  7. 6.3.2 North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032)
  10. 6.4.2 Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032)
  16. 6.6.2 South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Country, 2025 VS 2032
7 Taditional Chinese Medicine (TCM) for COVID-19 Country-level Value Analysis
  1. 7.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China Beijing Tong Ren Tang Group Co., Ltd.
  2. 8.1.1 China Beijing Tong Ren Tang Group Co., Ltd. Company Information
  3. 8.1.2 China Beijing Tong Ren Tang Group Co., Ltd. Business Overview
  4. 8.1.3 China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  6. 8.1.5 China Beijing Tong Ren Tang Group Co., Ltd. Recent Developments
  7. 8.2 Yiling Pharmaceutical
  8. 8.2.1 Yiling Pharmaceutical Company Information
  9. 8.2.2 Yiling Pharmaceutical Business Overview
  10. 8.2.3 Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  12. 8.2.5 Yiling Pharmaceutical Recent Developments
  13. 8.3 Southwest Pharmaceutical
  14. 8.3.1 Southwest Pharmaceutical Company Information
  15. 8.3.2 Southwest Pharmaceutical Business Overview
  16. 8.3.3 Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  18. 8.3.5 Southwest Pharmaceutical Recent Developments
  19. 8.4 Beijing Juxiechang Pharmaceutical
  20. 8.4.1 Beijing Juxiechang Pharmaceutical Company Information
  21. 8.4.2 Beijing Juxiechang Pharmaceutical Business Overview
  22. 8.4.3 Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  24. 8.4.5 Beijing Juxiechang Pharmaceutical Recent Developments
  25. 8.5 Jiuzhitang
  26. 8.5.1 Jiuzhitang Company Information
  27. 8.5.2 Jiuzhitang Business Overview
  28. 8.5.3 Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  30. 8.5.5 Jiuzhitang Recent Developments
  31. 8.6 Jiangsu Jichuan Holding Group Co., Ltd.
  32. 8.6.1 Jiangsu Jichuan Holding Group Co., Ltd. Company Information
  33. 8.6.2 Jiangsu Jichuan Holding Group Co., Ltd. Business Overview
  34. 8.6.3 Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  36. 8.6.5 Jiangsu Jichuan Holding Group Co., Ltd. Recent Developments
  37. 8.7 Tianjin Chase Sun Pharmaceutical
  38. 8.7.1 Tianjin Chase Sun Pharmaceutical Company Information
  39. 8.7.2 Tianjin Chase Sun Pharmaceutical Business Overview
  40. 8.7.3 Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  42. 8.7.5 Tianjin Chase Sun Pharmaceutical Recent Developments
  43. 8.8 Guizhou Yibai Pharmaceutical
  44. 8.8.1 Guizhou Yibai Pharmaceutical Company Information
  45. 8.8.2 Guizhou Yibai Pharmaceutical Business Overview
  46. 8.8.3 Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  48. 8.8.5 Guizhou Yibai Pharmaceutical Recent Developments
  49. 8.9 Sunflower
  50. 8.9.1 Sunflower Company Information
  51. 8.9.2 Sunflower Business Overview
  52. 8.9.3 Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  54. 8.9.5 Sunflower Recent Developments
  55. 8.10 Qingfeng Pharmaceutical Group
  56. 8.10.1 Qingfeng Pharmaceutical Group Company Information
  57. 8.10.2 Qingfeng Pharmaceutical Group Business Overview
  58. 8.10.3 Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  60. 8.10.5 Qingfeng Pharmaceutical Group Recent Developments
  61. 8.11 Jiren Pharmaceutical Group
  62. 8.11.1 Jiren Pharmaceutical Group Company Information
  63. 8.11.2 Jiren Pharmaceutical Group Business Overview
  64. 8.11.3 Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Product Portfolio
  66. 8.11.5 Jiren Pharmaceutical Group Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst